Why Analysts Favor Kiniksa Pharmaceuticals (KNSA)
On December 12, Wells Fargo analyst Eva Fortea Verdejo indicated her bullish sentiment and assigned a Buy rating to Kiniksa Pharmaceuticals International (NASDAQ:KNSA).
Kiniksa Pharmaceuticals International Plc (KNSA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rubric Capital Management David Rosen | 4,000,000 | $155,320,000 | +3% | 1.75% |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 2,824,669 | $109,681,897 | 0.79% | |
| 3. | Tang Capital Management Kevin C. Tang | 2,328,609 | $90,419,887 | 3.48% | |
| 4. | D E Shaw D. E. Shaw | 1,134,186 | $44,040,443 | +44% | 0.02% |
| 5. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 1,068,263 | $41,480,652 | +46% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $19.24 | 235,019 | $4,520,942.99 | 843,352 | 2018-05-29 | Filing | |
| $20.91 | 25,000 | $522,747.50 | 608,333 | 2018-05-29 | Filing | |
| $19.81 | 250,000 | $4,953,150.00 | 583,333 | 2018-05-29 | Filing | |
| $18.00 | 333,333 | $5,999,994.00 | 333,333 | 2018-05-29 | Filing | |
| $18.00 | 69,444 | $1,249,992.00 | 900,443 | 2018-05-29 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $41.89 | 12,000 | $502,680.00 | 19,086 | 2026-01-08 | Filing | |
| $41.51 | 20,129 | $835,554.79 | 12,546 | 2025-12-15 | Filing | |
| $41.56 | 12,048 | $500,714.88 | 16,666 | 2025-12-15 | Filing | |
| $41.49 | 42,841 | $1,777,473.09 | 31,086 | 2025-12-08 | Filing | |
| $42.89 | 200 | $8,578.00 | 22,714 | 2025-11-26 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 425,232 | $17,540,820 | 0.01% | |
| 2. | 400,598 | $16,524,668 | 0.03% | |
| 3. | 114,462 | $4,721,558 | 0.48% | |
| 4. | 110,682 | $4,539,069 | 0% | |
| 5. | 79,200 | $3,267,000 | 0.11% |
News See All
15 Most Promising Mid-Cap Healthcare Stocks Under $50
Traditionally, healthcare stocks have been considered defensive, offering strong immunity to business cycles.
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q3 2025 Earnings Call Transcript
Operator: Thank you for standing by. Welcome to the Kiniksa Pharmaceuticals Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded.
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q2 2025 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to the Kiniksa Pharmaceutical Second Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded.
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals First Quarter 2025 Earnings Conference Call.
10 Best UK Growth Stocks to Buy Now
The start of this year has marked interesting developments for the UK market.
12 Best Small Cap Pharma Stocks to Buy Now
Emily Field, Head of European Pharma Research at Barclays, spoke on CNBC on February 20 about the performance of obesity medications, the effects of US tariffs, and the dynamics of the pharmaceutical ...
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2024 Earnings Call Transcript
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2024 Earnings Call Transcript February 25, 2025Kiniksa Pharmaceuticals, Ltd. misses on earnings expectations.
10 Top Performing European Stocks Heading into 2025
As per Deloitte, inflation in the Eurozone slightly rebounded in October but was still quite low. The consumer price index increased 2% in October as compared to the year earlier.
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q3 2024 Earnings Call Transcript
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q3 2024 Earnings Call Transcript October 29, 2024Kiniksa Pharmaceuticals, Ltd. misses on earnings expectations.